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Background: Different ethnicities have different distribution of Duffy blood group (DBG) phenotypes and different
breast cancer morbidity. A study in our lab demonstrated that Duffy antigen/receptor for chemokines (DARC, also
known as DBGP, the Duffy protein phenotype), led to the inhibition of tumorigenesis. Therefore, we tested the
hypothesis that DBGP is correlated with breast cancer occurrence.
Methods: DBGP proteins were examined by indirect antiglobulin testing with anti-FYa and anti-FYb antibodies. The
phenotypes were classified into four groups according to the agglutination reactions: FYa + FYb+, FYa + FYb-,
FYa-FYb + and FYa-FYb-. The phenotypes and pathological diagnosis of consecutively hospitalized female patients
(n = 5,022) suffering from breast cancer at the Shanghai Cancer Hospital and Henan Province Cancer Hospital were
investigated. The relationships between DBGP expression with breast cancer occurrence, axillary lymph status,
histological subtype, tumor size pathological grade and overall survival were analyzed.
Results: The incidence of breast cancer was significantly different between FYa + FYb + (29.8%), FYa + FYb- (33.2%),
FYa-FYb + (45.6%) and FYa-FYb- (59.1%; P = 0.001). Significant different numbers of breast cancer patients had
metastases to the axillary lymph nodes in the FYa + FYb + group (25.1%), FYa + FYb- (36.9%), FYa-FYb + (41.0%) and
FYa-FYb- (50.0%, (P = 0.005). There was a statistical significance (p = 0.022) of the overall survival difference between
patients with difference phenotypes. No significant difference was observed in cancer size (t-test, p > 0.05),
histological cancer type (Fisher's exact test, p > 0.05) or histological grade (Fisher's exact test, p > 0.05) between
every each DBGP group.
Conclusions: DBGP is correlated with breast cancer incidence and axillary lymph node metastasis and overall
survival. Further investigations are required to determine the underlying mechanism of Duffy blood group
phenotype on breast cancer risk.
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Duffy blood group (DBG) system consists of genotype
systems, phenotype systems and five antigens. The geno-
type system of DBG consists of four alleles, FYA, FYB,
FYBES, and FYBWK. The DBG phenotype (DBGP) sys-
tem consists of five phenotypes [FYa + FYb+, FYa + FYb-,
FYa-FYb+, FYa-FYb + (wK), and FYa-FYb-]. In addition
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reproduction in any medium, provided the orsystem consists of five antigens (DBGP proteins), termed
FYa, FYb, FY3, FY5 and FY6 [1]. The majority of anti-
gens are FYa and FYb, which are encoded by the allelic
FYA and FYB genes. Anti-FYa and anti-FYb antibodies
define four red blood cell (RBC) phenotypes: FYa + FYb-,
FYa-FYb+, FYa + FYb+, and FYa-FYb- [2].
The DBGP system is embodied by proteins that carry
blood group antigens on the surfaces of RBC. These pro-
teins have the same structural and functional basis as
Duffy antigen/receptor for chemokines (DARC), which
is the chemokine decoy receptor on the surface of RBCs
and other cells [3,4]. The DBGP protein on the surfaces
of RBCs has the same structure and decoy function as
DARC, which was termed DBGP/DARC in this paper.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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can bind to members of the CXC and CC classes of che-
mokines, including interleukin-8 (IL-8), monocyte
chemotactic protein-1 (MCP-1) and RANTES (Regu-
lated on Activation, Normal T Expressed and Secreted)
[5,6]. These chemokines have been implicated in the
pathogenesis of breast cancer [7-9].
Besides these ligands are correlated with breast cancer,
DBGP/DARC has aroused the interest in cancer research
as it has been implicated in non-small cell lung cancer
tumorigenesis (NSCLC) [10], prostate cancer incidence
[11,12], and breast cancer development [13]. NSCLC
tumor cells that overexpress DBG have increased levels
of tumor necrosis [10]. DBGP/DARC clears angiogenic
CXC chemokines and reduced chemotaxis in the vascu-
lature [11,14]. Moreover, DBG interacts with a prostate
cancer metastasis suppressor gene, KAI1, and inhibits
the proliferation of prostate cancer cells [15,16].
Our previous studies have observed that breast cancer
lines, MDA-MB-231 and MDA-MB-435, that overex-
pressed DBGP/DARC induced the inhibition of tumori-
genesis through interfering with tumor angiogenesis in
rats, and this inhibition was associated with decreased
expression levels of CCL2 (Chemokine C-C motif ligand
2, one of DBGP/DARC ligand), decreased microvascular
density and decreased MMP-9 (matrix metalloprotei-
nase-9) expression in xenograft tumors [13]. Further-
more, the downregulation of DBG was associated with
lymph node metastasis in human breast cancer [17].
Moreover, different ethnicities have different distribu-
tion of Duffy blood group (DBG) phenotypes and differ-
ent breast cancer morbidity.
To date, no epidemiological study has validated the
above findings. Based on these previous findings, we
designed this study to assess whether there is a correl-
ation between Duffy blood group phenotype (DBGP/
DARC) and breast cancer incidence using a clinical epi-
demiological approach.Methods
Study subjects
This study was carried out on a series of 5,022 consecu-
tively hospitalized female patients (mean age, 50.5±13.1 yr;
range, 13–83 yr) with either benign or malignant breast dis-
ease. All patients were hospitalized at either the Shanghai
Cancer Hospital or Henan Province Cancer Hospital be-
tween July 15th, 2006 and November 14th, 2007. The proto-
col of this study was approved by the human research
committee of both hospitals, and informed consent was
obtained from each patient. All patients were followed-up
to determine their clinical outcome.
Patients were excluded from the study if they fulfilled
one or more of the following criteria: 1) no histologicaldiagnosis was obtained as the patient had not undergone
surgery or core biopsy (n = 62); 2) histology revealed a
malignant phyllodes tumor (n = 33) and so could not be
classified as either a breast cancer or a benign lesion;
and 3) patients had undergone neoadjuvent therapy
which could have influenced the postoperative histo-
logical diagnosis (n = 228). Overall, 323 patients were
excluded from the study and 5,022 patients were en-
rolled in this study.
Blood samples and test reagents
A 2-ml sample of whole blood was obtained in a glass
tube pretreated with EDTA (100 μg/mL), and stored at
4°C. Anti-FYa and Anti-FYb reagents were obtained
from Biotest Corporation (Germany). Anti-human glo-
bulins were obtained from the Shanghai Blood Center
(China), who kindly offered FYa- and FYb-positive or
-negative RBCs as a gift.
Indirect antiglobulin-test
Within 5 days of sampling, blood samples were sub-
jected to the indirect antiglobulin-test according to
standard procedures described in the instructions ac-
companying the reagents and previously published
methods [18]. The reaction strength was evaluated
according to the Technical Manual, 12th Edition, Section
1, American Association of Blood Banks.
A positive and a negative control were performed in a
parallel experiment. Patient phenotypes were classified
into four types: FYa + FYb+, FYa + FYb-, FYa-FYb + and
FYa-FYb- according to the presence or absence of FYa
and FYb antigens.
Pathological diagnosis
All of the histological diagnosis was based on formalin-
fixed paraffin-embedded sections. The pathological fea-
tures were reviewed by two experienced pathologists
who were specialized in breast pathology independently.
The chief pathological diagnosis was the determination
of whether a lesion was malignant or benign. The histo-
pathological features of breast cancer were reported, in-
cluding tumor size, histological cancer subtype and
pathological grade.
If the benign leision(s) and breast cancer(s) co-exist in
one patient, the patient is determined and subjected to
statistical analysis as breast cancer patient.
Statistical analysis
All statistical analyses were performed using SPSS (ver-
sion17.0). A P-value <0.05 was considered to be statisti-
cally significant. Between-group comparisons for the
incidence of breast cancer and axillary lymph node me-
tastasis in every DBGP group were performed with the
Chi-square test. The significance of overall survival
Table 1 The pathological diagnoses in a total of 5,022
female hospitalized patients†
Lesions Patients (total 5022)
breast cancer
DCIS (duct carcinoma in situ) 125
invasive lobular breast cancer 59











benign phyllodes tumor 20
total|| 4020
† 6,012 pathological diagnoses were obtained from 5,022 patients.
{ Includes 11 cases of supplementary radical operation and two cases of
occult breast cancer.
} 1,992 breast cancers in 1,962 patients; 26 pts out of 1,825 pts had bilateral
invasive cancers, three pts had invasive cancers and contralateral DCIS. One
patient out of 121 patients with DCIS had bilateral DCIS, 11 cases underwent a
supplementary radical operation, and two cases of occult breast cancer.
|| 3,855 breast benign lesions in 3,060 patients; 165 breast benign lesions in
the above 1,962 breast cancer patients.
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rank test. The difference in tumor size between DBGP
groups was analyzed by the Student's t-test. The differ-
ences in histological cancer types and histological grades
were compared using the Fisher's exact test.
Results
DBGPs distribution (DBGPD)
The details of a total of 5,022 consecutively enrolled
patients with 6,012 pathological diagnoses are summarizedTable 2 The numerical value and percentage of breast cancer
5,022 patients (6,012 pathological diagnoses)
DBGP Breast cancer Benign disease
Fya + Fyb+ 219(29.8%1) { 517(70.2%)




† DBGPF =DBGP frequency.
{ Among these 219 breast cancer, 11 were DCIS; one case was a supplementary rad
} Among these 219 breast cancers, one case supplementary radical operation was e
been removed.
|| Among these 1,698 breast cancers, 112 were DCIS, 10 cases were supplementary
} Among these 1,698 breast cancers, two cases of axillary lymph nodes biopsies we
occult breast cancer; 10 cases of supplemental radical operations were excluded fro
already been removed.in Table 1. There were 3,855 benign lesions in 3,060
patients, 1,992 breast cancers in 1,962 patients, and 165
additional benign lesions in the 1,962 patients with breast
cancer. Overall, 620 patients were FYa+FYb+ (12.3%),
4,262 were FYa+FYb- (84.9%), 120 were FYa-FYb+ (2.4%)
and 20 were FYa-FYb- (0.4%) (Table 2).
Breast cancer incidence and surgical treatment
Among the 1,992 breast cancers in 1,962 patients, 125
were DCIS and 1,867 were invasive breast cancers. Of
these, 26 out of the 1,825 patients had bilateral invasive
cancers, and three patients had invasive cancers and
contralateral DCIS. One patient out of the 125 patients
with DCIS had bilateral DCIS. Eleven patients had an
operable locoregional recurrence, and two patients had
occult breast cancers.
Among the 1,867 invasive breast cancers, 1,406
patients underwent total mastectomy and axillary dissec-
tion at levels I or II (modified radical mastectomy), 294
underwent breast-conserving surgery, 156 underwent
sentinel lymph node biopsies, and 11 patients with oper-
able locoregional recurrence underwent radical mastec-
tomy. Among the 125 patients with DCIS, 76 underwent
breast-conserving surgery, 35 underwent a total mastec-
tomy, and 14 patients with DCIS and microinvasion
underwent sentinel lymph node biopsies.
The relationship between DBGPD and breast cancer
incidence and overall survival
A statistically significant difference was observed be-
tween every DBG phenotype and breast cancer incidence
(29.8% were FYa + FYb+; 33.2% were FYa + FYb-; 45.6%
were FYa-FYb + and 59.1% were FYa-FYb-; P = 0.001;
Table 2).
There was a statistical significance (p = 0.022) of the
overall survival difference between patients with differ-
ence phenotypes (Figure 1). The overall survival curves
were generated using Kaplan-Meier method.cases and cancer size in different DBG phenotypes of
Total Cancer size DBGPF †}
736(100%) 26 ± 9} 620(12.3%)
5118(100%) 26 ± 10 4262(84.9%)
136(100%) 27 ± 9 120(2.4%)
22(100%) 29 ± 7 20(0.4%)
6012 5022(100%)
ical operation.
xcluded from statistics of cancer size because of primary breast cancers had
radical operations and two cases were occult breast cancers.
re excluded from the statistics regarding cancer size because the presence of
m the statistics regarding cancer size as the primary breast cancers had
Figure 1 The 5 year overall survival curves indicated a statistical significance (p =0.02) of the overall survival difference between
patients with difference phenotypes. The 5 year overall survival distribution was 91.0% in Fya + Fyb+, 86.5% in Fya + Fyb-, 83.3% in
Fya-Fyb + and 75.0% in Fya-Fyb-.
Table 4 The pathological grade of 1,867 invasive breast
cancers
DBGPs Grade I Grade II Grade III Total
FYa + FYb+ † 17 (9.0%) 135 (71.8%) 36 (19.1%) 188 (100%)
{
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No significant difference was observed between each
DBG phenotype and tumor size (Table 2; p > 0.05). A
statistically significant difference in the incidence of axil-
lary lymph node metastasis were observed in breast
cancer patients with FYa + FYb+ (25.1%), FYa + FYb-
(36.9%), FYa-FYb + (41.0%) and FYa-FYb- (50.0%;
P = 0.005) phenotypes (Table 3). The difference in patho-
logical grades between every DBG phenotype was not
significantly different (p > 0.05; Table 4). There was also
no correlation between DBGPs and the histological can-
cer subtypes (p > 0.05; Table 5). No significant difference
was observed between the DBG phenotype and patient
age (Student's t-test, p > 0.05) or menopausal status
(Fisher's Exact Test, p > 0.05; data not shown).
Discussion
Breast cancer incidence was higher in FYa-FYb+and FYa-FYb-
The results of the current study indicated that breast
cancer occurred at significantly higher levels (P = 0.001)Table 3 Axillary lymph node status of 1,867 invasive
breast cancers (absolute numbers and percentages)
DBGPs No metastasis Metastasis Total
FYa + FYb+ 155 (74.9%) 52 (25.1%) 207 (100%)
FYa + FYb- 1002 (63.1%) 585 (36.9%) 1587 (100%)
FYa-FYb+ 36 (59.0%) 25 (41.0%) 61 (100%)
FYa-FYb- 6 (50.0%) 6 (50.0%) 12 (100%)
Total 1199 (64.2%) 668 (35.8%) 1867 (100%)in patients with the FYa-FYb + (45.6%) and FYa-FYb-
(59.1%) phenotypes than the FYa + FYb + (29.8%) and
FYa + FYb- (33.2%) phenotypes. One potential mechan-
ism for this is that the DBG-ligand binding affinity on
RBC membranes differs between DBGPs, which may re-
sult in different degrees of tumorigenicity.
Tournamille et al. found that a chemokine-binding
pocket was defined by the close proximity of the first
and fourth transmembrane domains of the DBG/DARC
protein and also by the importance of the N-terminal
extracellular region correlated to chemokines binding to
the DBG protein [19,20]. Woolley et al. developed a flow
cytometric method to test the quantity of DBG on the
surface of RBCs [21]. They found that FY6 levels wereFYa + FYb- 105 (7.0%) 1077 (72.2%) 310 (20.8%) 1492 (100%)
FYa-FYb+ } 5 (8.2%) 38 (62.3%) 18 (29.5%) 61 (100%)
FYa-FYb- 1 (7.7%) 9 (69.2%) 3 (23.1%) 13 (100%)
Total 128 (7.3%) 1259 (71.8%) 367 (20.9%) 1754 (100%)
† 18 cases of FYa + FYb+phenotypes had no pathological grades as follows:
one case of supplementary radical surgery; three cases mucinous carcinoma;
14 cases of invasive lobular breast cancer.
{ 94 cases of FYa + FYb- phenotypes had not pathological grading as follows:
10 cases of supplementary radical operation; 45 cases of invasive lobular
breast cancer; 37 cases of mucinous carcinoma; two cases of occult breast
cancer.
} One case of mucinous carcinoma.
Table 5 Correlations between the histological type of 1,979 breast cancers and DBGP status (11 cases of
supplementary radical surgery and two cases of occult breast cancer were excluded)
DBGPs DCIS ILBC† IDBC{ MC} TC|| Total
FYa + FYb+ 11(5.0%) 12(5.5%) 184(84.8%) 3(1.4%) 8 (3.7%) 218(100%)}
FYa + FYb- 112(6.6%) 45(2.7%) 1431(84.9%) 37(2.2%) 61(3.6%) 1686(100%)††
FYa-FYb+ 1 (1.6%) 1 (1.6%) 57(91.9%) 1(1.6%) 2(3.2%) 62(100%)
FYa-FYb- 1 (7.7%) 1(7.7%) 11(84.6%) 0 0 13(100%)
Total 125 59 1683 41 71 1979
† ILBC = invasive lobular breast cancer.
{ IDBC = invasive ductal breast carcinoma.
} MC=mucinous carcinoma.
|| TC = tubular carcinoma.
} One case of supplementary radical operation.
†† 10 cases of supplementary radical surgery and two cases of occult breast cancer were excluded because of the lack of a primary lesion.
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genotype than on those of the FYA/FYA or FYA/FYB
genotype. Beside this, 5,000-10,000 DBG molecules were
found on a single RBC. Horuk et al. developed satur-
ation binding studies on a erythroleukemic cell line
(HEL) and observed that the DBG density was 12,818
+/− 965 binding sites for every cell [5]. These data sug-
gested that RBCs with abundant DBG expression on
their surfaces might clear many angiogenic CXC chemo-
kines and decrease chemotaxis in patients with breast
cancer. Thereafter, the tumorigenicity of breast cancer
cells could be attenuated.
Woolley et al. indicated that Fy6 levels were signifi-
cantly lower on reticulocytes and mature RBCs of the
FYB/FYB genotype (encoding the FYa-FYb + phenotype)
than on those of the FYA/FYA (encoding the FYa + FYb-
phenotype) or FYA/FYB genotypes (encoding FYa + FYb
+) [21]. Moreover, the FYa + FYb+ phenotype presented
the FYa and FYb antigens, FYa + FYb- presented the FYa
antigen had no FYb antigens, and so on. Based on these
published reports, we tentatively propose that different
DBGPs had different quantities and/or quality of DBG
expression on the surface of every RBC. There might be
more Duffy antigens expressed on one RBC belonging to
an individual with the FYa + FYb+ phenotype and a
FYa + FYb- individual than on FYa-FYb + or FYa-FYb-
individuals. Consequently, FYa + FYb+ and FYa + FYb-
individuals would have higher chemokine binding
capacities than FYa-FYb + and FYa-FYb- individuals, and
the FYa + FYb + and FYa + FYb- phenotype offer more
protection against breast cancer than the FYa-FYb + and
FYa-FYb- phenotypes. Therefore, patients with the
former two phenotypes appear to be at a lower risk of
breast cancer than patients who express the latter two
phenotypes.
DBGPD and tumor size and axillary lymph nodes status
A previous study had indicated that there was no differ-
ence in the frequencies of DBGPs between breast cancer
patients compared to a healthy Han population in China(data not shown) [22]. One possible reason for no sig-
nificant difference in tumor size between each DBGP
was that these patients were only diagnosed when their
mass was great enough to be discovered. A subclinical
period was therefore present before this point.
Significantly more breast cancer patients had axillary
lymph node metastases with in FYa-FYb- (50.0%) and
FYa-FYb + (41.0%) than that of FYa + FYb- (36.9%) and
FYa + FYb+ (25.1%), which confirmed our hypothesis.
The regular pattern of tumor size as a predictor of axil-
lary node metastases in patients with breast cancer was
generally applicable in the clinical practice. However,
even patients with small tumours (0-5 mm) have the
possibility of axillary involvement (7–14.5%) [23]. The
above-described potential mechanism for different
DBGPs resulting in different degrees of tumorigenicity
might explain this finding.Study limitations
Firstly, study subjects were all female patients who were
already suffering from breast diseases, and no healthy
population was studied prospectively. Therefore, further
studies of this protein are required. Secondly, this de-
scriptive and explorative study deduced the mechanism
of the link between different DBGPs and breast cancer
theoretically, and further studies into the underlying mo-
lecular mechanisms are warranted.Conclusions
DBGPs have a statistically significant effect on breast
cancer incidence and the likelihood of axillary lymph
node metastasis.
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